7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Osteoarthritis, Knee D020370 13 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Fractures, Stress D015775 2 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Thyroid Diseases D013959 8 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Myocardial Ischemia D017202 11 associated lipids
Paraneoplastic Syndromes D010257 4 associated lipids
Sepsis D018805 11 associated lipids
Periodontal Pocket D010514 9 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Yang X et al. Effects of TGF-β1 on OPG/RANKL expression of cementoblasts and osteoblasts are similar without stress but different with mechanical compressive stress. 2015 ScientificWorldJournal pmid:25685846
Zhang Q et al. Local gene transfer of OPG prevents joint damage and disease progression in collagen-induced arthritis. 2013 ScientificWorldJournal pmid:24222748
Teitelbaum SL Bone resorption by osteoclasts. 2000 Science pmid:10968780
Wickelgren I Mining the genome for drugs. 1999 Science pmid:10475849
Warren JT et al. Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members. 2014 Sci Signal pmid:25140055
Zang L et al. The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis. 2015 Sci Rep pmid:26671549
Schiro A et al. Elevated levels of endothelial-derived microparticles, and serum CXCL9 and SCGF-β are associated with unstable asymptomatic carotid plaques. 2015 Sci Rep pmid:26564003
Mizuno M et al. Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease. 2015 Sci Rep pmid:26561427
Nemeth ZK et al. Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. 2015 Sci Rep pmid:26459001
Wang B et al. Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone. 2015 Sci Rep pmid:26329493
Kao SY and Stankovic KM Transactivation of human osteoprotegerin promoter by GATA-3. 2015 Sci Rep pmid:26216189
Hope S et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. 2013 Schizophr. Res. pmid:23403415
Dieset I et al. Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein. 2012 Schizophr. Res. pmid:22817875
Gehrke T et al. Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. 2003 Scand. J. Rheumatol. pmid:14690142
Spelling P et al. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? 2008 Nov-Dec Scand. J. Rheumatol. pmid:18802807
Sennels H et al. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. 2008 Jul-Aug Scand. J. Rheumatol. pmid:18612923
Feuerherm AJ et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. 2001 Scand. J. Rheumatol. pmid:11578019
Reenaers C et al. Sensitivity of intestinal fibroblasts to TNF-related apoptosis-inducing ligand-mediated apoptosis in Crohn's disease. 2008 Scand. J. Gastroenterol. pmid:18942021
Yilmaz Y et al. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. 2010 Scand. J. Clin. Lab. Invest. pmid:20942739
Grauslund J et al. Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes? 2010 Scand. J. Clin. Lab. Invest. pmid:20205614
Bjerre M et al. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. 2014 Scand. J. Clin. Lab. Invest. pmid:25026506
Sennels HP et al. Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein. 2007 Scand. J. Clin. Lab. Invest. pmid:17852826
Knudsen ST et al. Plasma concentrations of osteoprotegerin during normo- and hyperglycaemic clamping. 2007 Scand. J. Clin. Lab. Invest. pmid:17365993
Altinova AE et al. Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. 2011 Scand. J. Clin. Lab. Invest. pmid:21486111
Muñoz-Calvo MT et al. Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa. 2007 Scand. J. Clin. Lab. Invest. pmid:17558893
Hosbond SE et al. Osteoprotegerin as a marker of atherosclerosis: a systematic update. 2012 Scand. Cardiovasc. J. pmid:22506827
Stenman UH et al. Prognostic value of serum markers for prostate cancer. 2005 Scand J Urol Nephrol Suppl pmid:16019759
Mohamed GB and Abdel-Latif EA Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome. 2011 Saudi J Kidney Dis Transpl pmid:21912025
Takayanagi H [Crosstalk between the immune and skeletal system]. 2003 Ryumachi pmid:14598653
Gurban CV and Mederle O The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. 2011 Rom J Morphol Embryol pmid:22119834
Grigorie D et al. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. 2003 Rom J Intern Med pmid:15526523
Grzegorzewska AE and MÅ‚ot M Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. 2004 Rocz. Akad. Med. Bialymst. pmid:15631341
Grzegorzewska AE and MÅ‚ot M Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. 2004 Rocz. Akad. Med. Bialymst. pmid:15631342
Naumnik W et al. Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer. 2004 Rocz. Akad. Med. Bialymst. pmid:15638385
Fukagawa M et al. [PTH and bone metabolism in chronic dialysis patients]. 2001 Rinsho Byori pmid:11307321
Haynes DR et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. 2001 Rheumatology (Oxford) pmid:11426018
Kim HR et al. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). 2006 Rheumatology (Oxford) pmid:16567356
Corallini F et al. The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. 2009 Rheumatology (Oxford) pmid:19168833
Smith MD Comment on review on T cells in bone biology. 2004 Rheumatology (Oxford) pmid:15448222
Pettit AR et al. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. 2006 Rheumatology (Oxford) pmid:16490750
Bezerra MC et al. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. 2005 Rheumatology (Oxford) pmid:16219645
Kwan Tat S et al. Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. 2009 Rheumatology (Oxford) pmid:19762475
Castellino G et al. The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker? 2010 Rheumatology (Oxford) pmid:20299382
Varsani H et al. Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). 2003 Rheumatology (Oxford) pmid:12649407
Engvall IL et al. Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP--a possible mechanism for specific inhibition of radiological destruction. 2013 Rheumatology (Oxford) pmid:23275387
Huang CH et al. Osteoprotegerin genetic polymorphisms and age of symptom onset in ankylosing spondylitis. 2011 Rheumatology (Oxford) pmid:20974615
Hofbauer LC et al. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. 2006 Rheumatology (Oxford) pmid:16574701
Breland UM et al. Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease. 2010 Rheumatology (Oxford) pmid:20231178
Haynes DR et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. 2003 Rheumatology (Oxford) pmid:12509625
Harashima SI et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients. 2004 Rheumatology (Oxford) pmid:14963213

Table of Content